<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The pathogenesis of <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> in <z:hpo ids='HP_0002099'>asthma</z:hpo> patients has not been fully elucidated </plain></SENT>
<SENT sid="1" pm="."><plain>Adverse drug effects, particularly those of β2-mimetics, may play a role </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to determine whether <z:hpo ids='HP_0002099'>asthma</z:hpo> is associated with the risk of <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> and electrocardiographic characteristics of arrhythmogenicity (ECG) and to explore the role of β2-mimetics </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: A cross-sectional study was conducted among 158 adult patients with a diagnosis of <z:hpo ids='HP_0002099'>asthma</z:hpo> and 6303 participants without <z:hpo ids='HP_0002099'>asthma</z:hpo> from the cohort of the Utrecht Health Project-an ongoing, longitudinal, primary care-based study </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients underwent extensive examinations, including resting 12-lead electrocardiogram (ECG) and pulmonary function tests </plain></SENT>
<SENT sid="5" pm="."><plain>The primary outcome was "any <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> on the ECG" (including <z:hpo ids='HP_0001649'>tachycardia</z:hpo>, <z:hpo ids='HP_0001662'>bradycardia</z:hpo>, <z:mp ids='MP_0009732'>premature ventricular contraction</z:mp> (<z:mp ids='MP_0010018'>PVC</z:mp>), and <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> or flutter) </plain></SENT>
<SENT sid="6" pm="."><plain>Secondary outcomes were <z:hpo ids='HP_0001649'>tachycardia</z:hpo>, <z:hpo ids='HP_0001662'>bradycardia</z:hpo>, <z:mp ids='MP_0010018'>PVC</z:mp>, <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> or flutter, mean heart rate, mean corrected QT (QTc) interval length, and <z:hpo ids='HP_0005184'>prolonged QTc interval</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: <z:hpo ids='HP_0001649'>Tachycardia</z:hpo> and <z:mp ids='MP_0010018'>PVCs</z:mp> were more prevalent in patients with <z:hpo ids='HP_0002099'>asthma</z:hpo> (3% and 4%, respectively) than those without <z:hpo ids='HP_0002099'>asthma</z:hpo> (0.6%, p &lt; .001; 2%, p = .03, respectively) </plain></SENT>
<SENT sid="8" pm="."><plain>The prevalence of QTc interval prolongation was similar in participants with (2%) and without <z:hpo ids='HP_0002099'>asthma</z:hpo> (3%, odds ratio [OR]: 0.6 and 95% confidence interval [95% CI]: 0.2-2.0) </plain></SENT>
<SENT sid="9" pm="."><plain>In 74 <z:hpo ids='HP_0002099'>asthma</z:hpo> patients, who received β2-mimetics, <z:hpo ids='HP_0001649'>tachycardia</z:hpo> and <z:mp ids='MP_0010018'>PVCs</z:mp> were more common (OR: 12.4 [95% CI: 4.7-32.8] and 3.7 [95% CI: 1.3-10.5], respectively) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: The adult patients with <z:hpo ids='HP_0002099'>asthma</z:hpo> more commonly show <z:hpo ids='HP_0001649'>tachycardia</z:hpo> and <z:mp ids='MP_0010018'>PVCs</z:mp> on the ECG than those without <z:hpo ids='HP_0002099'>asthma</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>The patients with <z:hpo ids='HP_0002099'>asthma</z:hpo> received β2-mimetics; the risk of <z:hpo ids='HP_0001649'>tachycardia</z:hpo> and <z:mp ids='MP_0010018'>PVCs</z:mp> is even more pronounced </plain></SENT>
</text></document>